Eduardo Ruiz-Hernández

Dr. Eduardo Ruiz-Hernández

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RMRebecca Maher
Rebecca Maher
AMAlmudena Moreno-Borrallo
Almudena Moreno-Borrallo
DJDhruvi Jindal
Dhruvi Jindal
BMBinh T. Mai
Binh T. Mai
Eduardo Ruiz-HernándezEduardo Ruiz-Hernández
Eduardo Ruiz-Hernández
AHAndrew Harkin
Andrew Harkin
Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous system (CNS) due to their safety profiles, drug-loading capacity, and controlled-release properties. Polymer and lipid-based nanoparticles (NPs) are reported to penetrate the blood–brain barrier (BBB) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. Since approval by the Food and Drug Administration (FDA) of intranasal esketamine for treatment of major depressive disorder, intranasal administration has emerged as an attractive route to bypass the BBB for drug delivery to the CNS. NPs can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. In this review, unique characteristics of polymeric and lipid-based nanocarriers desirable for drug delivery to the brain are explored in addition to their potential for drug repurposing for the treatment of CNS disorders. Progress in intranasal drug delivery using polymeric and lipid-based nanostructures for the development of treatments of various neurological diseases are also described.

11 May 2018 in Materials
Verified
Journal Article
Open access
PDF file
LNL. Nam
L. Nam
CCC. Coll
C. Coll
LSLuiza Dos Santos
Luiza Dos Santos
CTC. De la Torre
C. De la Torre
DSDolores R Serrano
Dolores R Serrano
Eduardo Ruiz-HernándezEduardo Ruiz-Hernández
Eduardo Ruiz-Hernández
Glioblastoma multiforme is one of the most prevalent and malignant forms of central nervous system tumors. The treatment of glioblastoma remains a great challenge due to its location in the intracranial space and the presence of the blood–brain tumor barrier. There is an urgent need to develop novel therapy approaches for this tumor, to improve the clinical outcomes, and to reduce the rate of recurrence and adverse effects associated with present options. The formulation of therapeutic agents in nanostructures is one of the most promising approaches to treat glioblastoma due to the increased availability at the target site, and the possibility to co-deliver a range of drugs and diagnostic agents. Moreover, the local administration of nanostructures presents significant additional advantages, since it overcomes blood–brain barrier penetration issues to reach higher concentrations of therapeutic agents in the tumor area with minimal side effects. In this paper, we aim to review the attempts to develop nanostructures as local drug delivery systems able to deliver multiple agents for both therapeutic and diagnostic functions for the management of glioblastoma.

1 December 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MEMerel van Elk
Merel van Elk
BMBruce P. Murphy
Bruce P. Murphy
TETatiane Eufrásio-Da-Silva
Tatiane Eufrásio-Da-Silva
DODaniel P. O’rEilly
Daniel P. O’rEilly
TVTina Vermonden
Tina Vermonden
Eduardo Ruiz-HernándezEduardo Ruiz-Hernández
Eduardo Ruiz-Hernández

1 January 2017 in Acta Biomaterialia
Verified
Journal Article
Closed access
HOHugh S. O’nEill
Hugh S. O’nEill
CHCaroline C. Herron
Caroline C. Herron
CHConn L. Hastings
Conn L. Hastings
RDRoel Deckers
Roel Deckers
ANAdolfo Lopez Noriega
Adolfo Lopez Noriega
GDGarry P Duffy
Garry P Duffy

1 February 2021 in Acta Biomaterialia
Verified
Journal Article
Open access
LSLuiza Dos Santos
Luiza Dos Santos
Oliviero L. GobboOliviero L. Gobbo
Oliviero L. Gobbo
Eduardo Ruiz-HernándezEduardo Ruiz-Hernández
Eduardo Ruiz-Hernández
The treatment for glioblastoma multiforme (GBM) has not changed for more than 20 years while the prognosis for the patients is still poor and most of them survive less than 1 year after diagnosis. The standard of care for GBM is comprised of surgical resection followed by radiotherapy and oral chemotherapy with temozolomide. The placement of carmustine wafers in the brain after tumour removal is added in cases of recurrent glioma. Significant research is underway to improve the GBM therapy outcome and patient quality of life. Biomaterials are in the front line of the research focus for new treatment options. Specially, biocompatible polymers have been proposed in hydrogel-based formulations aiming at injectable and localized therapies. These formulations can comprise many different pharmacological agents such as chemotherapeutic drugs, nanoparticles, cells, nucleic acids, and diagnostic agents. In this manuscript, we review the most recent formulations developed and tested both in vitro and in vivo using different types of hydrogels. Firstly, we describe three common types of thermo-responsive polymers addressing the advantages and drawbacks of their formulations. Then, we focus on formulations specifically developed for GBM treatment.

29 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LELuiza C. S. Erthal
Luiza C. S. Erthal
YSYang Shi
Yang Shi
KSKieron J. Sweeney
Kieron J. Sweeney
OGOliviero L. Gobbo
Oliviero L. Gobbo
Eduardo Ruiz-HernándezEduardo Ruiz-Hernández
Eduardo Ruiz-Hernández
Malignant gliomas are a type of primary brain tumour that originates in glial cells. Among them, glioblastoma multiforme (GBM) is the most common and the most aggressive brain tumour in adults, classified as grade IV by the World Health Organization. The standard care for GBM, known as the Stupp protocol includes surgical resection followed by oral chemotherapy with temozolomide (TMZ). This treatment option provides a median survival prognosis of only 16–18 months to patients mainly due to tumour recurrence. Therefore, enhanced treatment options are urgently needed for this disease. Here we show the development, characterization, and in vitro and in vivo evaluation of a new composite material for local therapy of GBM post-surgery. We developed responsive nanoparticles that were loaded with paclitaxel (PTX), and that showed penetration in 3D spheroids and cell internalization. These nanoparticles were found to be cytotoxic in 2D (U-87 cells) and 3D (U-87 spheroids) models of GBM. The incorporation of these nanoparticles into a hydrogel facilitates their sustained release in time. Moreover, the formulation of this hydrogel containing PTX-loaded responsive nanoparticles and free TMZ was able to delay tumour recurrence in vivo after resection surgery. Therefore, our formulation represents a promising approach to develop combined local therapies against GBM using injectable hydrogels containing nanoparticles.